Olanzapine vs Haloperidol for Treatment of Schizophrenia [1] (multiple letters)

JAMA

Volumn 291, Issue 9, 2004, Pages 1064-1066

  Volavka, Jan ^a   Citrome, Leslie ^a   Glazer, William M ^b   Amin, Mo ^c   Shukla, Vijay S ^c   Kunz, Michal ^d   De Haan, Lieuwe ^e   Van Beveren, Nico ^f   Rosenheck, Robert ^g   Perlick, Deborah ^g   Bingham, Stephen ^g   Collins, Joseph ^g  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Canadian Coordinating Office for Health Technology Assessment   (Canada)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE; ANTIPARKINSON AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LETTER; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; AKATHISIA; ECONOMICS; NOTE; EPIDEMIOLOGY;

AKATHISIA, DRUG-INDUCED; ANTI-DYSKINESIA AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BENZTROPINE; HALOPERIDOL; HUMANS; SCHIZOPHRENIA; SELECTION BIAS;

EID: 10744223135     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.9.1064-a     Document Type: Letter

References (0)